NWS
58
-4
EFX
54
-11
RIG
40
-3
CSX
43
2
ABT
54
-2
EXC
63
2
UHS
56
-3
CMCSA
57
4
CNX
65
-3
CNP
49
-8
JCI
46
2
JWN
53
5
NUE
47
-3
CLX
53
2
PNW
57
2
HSY
41
3
KO
47
3
CRM
42
-2
VIX
69
-2
XEL
55
5
NWS
58
-4
EFX
54
-11
RIG
40
-3
CSX
43
2
ABT
54
-2
EXC
63
2
UHS
56
-3
CMCSA
57
4
CNX
65
-3
CNP
49
-8
JCI
46
2
JWN
53
5
NUE
47
-3
CLX
53
2
PNW
57
2
HSY
41
3
KO
47
3
CRM
42
-2
VIX
69
-2
XEL
55
5
Financhill
Back

Taro Pharmaceutical Industries 10K Form

Buy
70

TARO
Taro Pharmaceutical Industries

Last Price:
42.22
Seasonality Move:
6.3%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TARO News And Ratings

See the #1 stock for the next 7 days that we like better than TARO

TARO Financial Statistics

Sales & Book Value

Annual Sales: $572.95M
Cash Flow: $-3.55M
Price / Cash Flow: 18.44
Annual Sales: $47.34
Price / Book: 0.89

Profitability

EPS (TTM): 1.22000
Net Income (TTM): $45.7M
Gross Margin: $268.32M
Return on Equity: 2.63%
Return on Assets: 2.14%

Taro Pharmaceutical Industries Earnings Forecast

Key Taro Pharmaceutical Industries Financial Ratios

  • The Gross Profit Margin over the past 37 years for TARO is 46.83%.
  • The Selling, General & Administrative Expenses for TARO have been equal to 34.62% of Gross Profit Margin.
  • The Research & Development expenses have been 9.12% of Revenue.
  • The Interest Expense is 4.92% of Operating Income.
  • The Net Earning history of TARO is 4.44% of Total Revenues.
  • Per Share Earnings over the last 36 years have been positive in 19 years.

Taro Pharmaceutical Industries Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TARO
CUSIP: M8737E
Website: taro.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.6
Quick Ratio: 3.03

Price-to-Earnings

Trailing P/E Ratio: 62.04
Forward P/E Ratio: 0

TARO Technical Analysis vs Fundamental Analysis

Buy
70
Taro Pharmaceutical Industries (TARO) is a Buy

Is Taro Pharmaceutical Industries a Buy or a Sell?